PhaseBio Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease

MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun dosing subjects in a Phase 1 clinical study with its novel compound, VasomeraTM (PB1046), in patients with Stage 1 and 2 essential hypertension. VasomeraTM is a VPAC2-selective Vasoactive Intestinal Peptide (VIP) agonist which has been genetically engineered using t

Feed Date: 
February 22, 2012